Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 16/20 | 0.81 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.81 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.81 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.81 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.81 |
| ▸ | GABRP | O00591 | 1/20 | 0.78 |
| ▸ | GABRD | O14764 | 1/20 | 0.78 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.78 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.78 |
| ▸ | PGR | P06401 | 1/20 | 0.78 |
| ▸ | KLK3 | P07288 | 1/20 | 0.78 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.78 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.78 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.78 |
| ▸ | CNR1 | P21554 | 1/20 | 0.78 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.78 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.78 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.78 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.78 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL582006 | 0.95 | AR (0.80) | ARHDAC6HDAC2HDAC3HDAC1 | |
| SCHEMBL24684767 | 0.92 | HDAC6 (0.84) | ARHDAC6HDAC2HDAC3HDAC1 | |
| SCHEMBL22198004 | 0.92 | AR (0.85) | ARHDAC6HDAC2HDAC3HDAC1 | |
| SCHEMBL20465765 | 0.92 | AR (0.83) | ARHDAC6HDAC2HDAC3HDAC1 | |
| SCHEMBL30893444 | 0.92 | HDAC6 (0.83) | ARHDAC6HDAC2HDAC3HDAC1 | |
| SCHEMBL21727673 | 0.92 | AR (0.69) | ARHDAC6HDAC2HDAC3HDAC1 | |
| SCHEMBL23113295 | 0.91 | HDAC6 (0.86) | ARHDAC6HDAC2HDAC3HDAC1 | |
| SCHEMBL30872754 | 0.91 | HDAC6 (0.86) | ARHDAC6HDAC2HDAC3HDAC1 | |
| SCHEMBL24684762 | 0.91 | AR (0.83) | ARHDAC6HDAC2HDAC3HDAC1 | |
| SCHEMBL24684748 | 0.90 | AR (0.82) | ARHDAC6HDAC2HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210069154-A1 | Treatment of Breast Cancer | MEDIVATION PROSTATE THERAPEUTICS LLC | 2021-03-11 | — | — | US | disclosed |
| EP-3610731-A1 | TREATMENT OF BREAST CANCER | Medivation Prostate Therapeutics LLC (US) | 2020-02-19 | — | — | EP | disclosed |
| US-20190262315-A1 | Treatment of Breast Cancer | MEDIVATION PROSTATE THERAPEUTICS, INC. | 2019-08-29 | — | — | US | disclosed |
| EP-3430907-A1 | TREATMENT OF BREAST CANCER | Medivation Prostate Therapeutics LLC (US) | 2019-01-23 | — | — | EP | disclosed |
| US-20170087132-A1 | Treatment of Breast Cancer | MEDIVATION PROSTATE THERAPEUTICS LLC | 2017-03-30 | — | — | US | disclosed |
| US-9517229-B2 | Treatment of breast cancer | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-20140296312-A1 | TREATMENT OF BREAST CANCER | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2014-10-02 | — | — | US | disclosed |
| US-8710086-B2 | Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods of use thereof | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| WO-2013066440-A9 | TREATMENT OF BREAST CANCER | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2013-07-18 | — | — | WO | disclosed |
| WO-2013066440-A1 | TREATMENT OF BREAST CANCER | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20120184580-A1 | SUBSTITUTED DI-ARYLHYDANTOIN AND DI-ARYLTHIOHYDANTOIN COMPOUNDS AND METHODS OF USE THEREOF | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| EP-2416657-A1 | SUBSTITUTED DI-ARYLHYDANTOIN AND DI-ARYLTHIOHYDANTOIN COMPOUNDS AND METHODS FOR USE THEREOF | Medivation Prostate Therapeutics, Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010118354-A1 | SUBSTITUTED DI-ARYLHYDANTOIN AND DI-ARYLTHIOHYDANTOIN COMPOUNDS AND METHODS FOR USE THEREOF | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010118354-A1 | SUBSTITUTED DI-ARYLHYDANTOIN AND DI-ARYLTHIOHYDANTOIN COMPOUNDS AND METHODS FOR USE THEREOF | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184580-A1 | SUBSTITUTED DI-ARYLHYDANTOIN AND DI-ARYLTHIOHYDANTOIN COMPOUNDS AND METHODS OF USE THEREOF | AR, BRDT, AADAC | AR 1/4885HDAC6 1206/4885HDAC2 325/4885 |
| US-20190262315-A1 | Treatment of Breast Cancer | BRCA1, TP53, TUBB6 | AR 2403/4885HDAC6 1217/4885HDAC2 3547/4885 |
| US-20170087132-A1 | Treatment of Breast Cancer | BRCA1, MKI67, BAX | AR 2292/4885HDAC6 320/4885HDAC2 1837/4885 |
| US-20140296312-A1 | TREATMENT OF BREAST CANCER | BRCA1, BAX, BAD | AR 2166/4885HDAC6 541/4885HDAC2 2462/4885 |
| US-20210069154-A1 | Treatment of Breast Cancer | BRCA1, TP53, TUBB6 | AR 2403/4885HDAC6 1217/4885HDAC2 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.